Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 26

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Deafness neurosensory+1

Recruiting

Study on the Effects of Intracochlear Triamcinolone Acetonide for Patients with Persistent Sudden Sensorineural Hearing Loss After Unsuccessful Conservative Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Triamcinolone Acetonide
  • Sponsor:Medical University Of Vienna

Intracranial aneurysm

Recruiting

Study on Managing Risk Factors in Patients with Unruptured Brain Aneurysms Using Carbasalate Calcium and Intensive Blood Pressure Treatment

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Heidelberg University

Nervous system disorder

Recruiting

Study on the Physical Impact of Multiple Sclerosis and Continued Access to Ocrelizumab for Patients Previously in a Related Study

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Subarachnoid haemorrhage

Recruiting

Study on the Effectiveness of Sphenopalatine Block for Headache Relief in Patients with Subarachnoid Hemorrhage Using Lidocaine Hydrochloride

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Neuromyelitis optica spectrum disorder

Recruiting

Study of Satralizumab for Children with Neuromyelitis Optica Spectrum Disorder (NMOSD)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Satralizumab
  • Sponsor:F. Hoffmann-La Roche AG

Amyotrophic lateral sclerosis+2

Recruiting

Study on Cannabis Extract for Improving Quality of Life in Patients with Alzheimer's, Parkinson's, or ALS Using Dronabinol and Cannabidiol

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cannabidiol
  • Sponsor:Azienda Ospedaliero-Universitaria Maggiore Della Carita

Anal incontinence

Recruiting

Study on the Effects of Botulinum Toxin Type A and a Drug Combination on Rectal Function in Patients with Fecal Incontinence

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Centre Hospitalier Universitaire Rouen

Neoplasm+2

Recruiting

Study on APL-101 for Treating Advanced Solid Tumors and Non-Small Cell Lung Cancer with MET Changes in Patients

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:APL-101
  • Sponsor:Apollomics Inc.

Neurogenic bladder

Recruiting

Study on the Safety and Effectiveness of Vibegron for Children Aged 2 to 17 with Neurogenic Bladder Overactivity Using Clean Intermittent Catheterization

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Vibegron
  • Sponsor:Sumitomo Pharma America Inc.

Migraine

Recruiting

Study on Rimegepant for Preventing Migraines in Children and Teens Aged 6 to 17

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Myasthenia gravis

Recruiting

Study of Efgartigimod PH20 SC for Children Aged 2 to 17 with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Malignant glioma

Recruiting

Study of tovorafenib (DAY101) in children and young adults aged 6 months to 25 years with brain tumors and other solid tumors that have RAF gene changes

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Tovorafenib
  • Sponsor:Day One Biopharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.